Liver Angiosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Liver Angiosarcoma Market Outlook

Thelansis’s “Liver Angiosarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Liver Angiosarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Liver Angiosarcoma Overview

Angiosarcoma is a highly malignant neoplasm originating from the endothelial cells of blood or lymphatic vessels. It is characterized by the formation of abundant vascular channels due to the proliferation of spindle or pleomorphic cells that line or grow into the lumina of preexisting vascular spaces. In adults, primary hepatic angiosarcoma is the liver's most common primary malignant mesenchymal tumor. The etiology of the majority of these tumors remains unknown. However, several factors have been identified, including exposure to industrial materials, iatrogenic exposure to certain substances, and chronic ingestion of certain toxins. Hepatic angiosarcoma manifests as a hepatic bleeding mass and can sometimes present as a solid tumor. The tumor tends to metastasize to the lungs and hilar lymph nodes and spread to other organs such as the spleen and bones. Clinical tumour staging is based on the American Joint Committee on Cancer Staging System for soft tissue sarcoma, which considers factors such as tumor size, depth, and the presence of regional lymph nodes and distant metastases. Differential diagnosis of hepatic angiosarcoma includes inflammatory disorders of the liver, benign vascular diseases of the liver, and Kaposi sarcoma. The prognosis for patients with hepatic angiosarcoma is poor, with most patients dying within six months of diagnosis. Even with treatment, only a few patients survive beyond two years. Hepatic angiosarcoma is a rare tumor of the liver.

• According to estimates, approximately 25 cases of this tumor occur annually in the United States.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: